Liquidia (NASDAQ:LQDA) Stock Falls 6.1% After Analyst Downgrade

Liquidia Corporation (NASDAQ:LQDA) fell 6.1% on Monday after Wells Fargo & Company downgraded the stock from an overweight rating to an equal weight rating. Wells Fargo & Company now has a $30.00 price target on the stock, down from their previous price target of $108.00. Liquidia traded as low as $25.92 and last traded at $26.8880. Approximately 1,088,644 shares changed hands during trading, a decline of 44% from the average session volume of 1,950,457 shares. The stock had previously closed at $28.64.

A number of other research analysts also recently issued reports on the company. Raymond James Financial downgraded Liquidia from a “strong-buy” rating to an “outperform” rating and cut their price objective for the company from $106.00 to $53.00 in a research note on Thursday, October 1st. Lifesci Capital downgraded shares of Liquidia from an “outperform” rating to a “hold” rating and set a $90.00 price target on the stock. in a report on Wednesday, August 12th. Bank of America lifted their price target on shares of Liquidia from $79.00 to $92.00 and gave the company a “neutral” rating in a report on Thursday, August 13th. Stephens set a $130.00 price target on shares of Liquidia in a research report on Friday, July 24th. Finally, BTIG Research cut shares of Liquidia from a “buy” rating to a “neutral” rating in a research note on Thursday, October 1st. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $83.69.

Insider Transactions at Liquidia

In related news, insider Rajeev Saggar sold 50,000 shares of Liquidia stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $74.06, for a total value of $3,703,000.00. Following the completion of the transaction, the insider owned 142,265 shares in the company, valued at approximately $10,536,145.90. This trade represents a 26.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Katherine Rielly-Gauvin sold 18,393 shares of Liquidia stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $72.23, for a total value of $1,328,526.39. Following the completion of the transaction, the director owned 44,637 shares of the company’s stock, valued at approximately $3,224,130.51. This represents a 29.18% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 522,519 shares of company stock worth $40,040,514. 25.60% of the stock is currently owned by corporate insiders.

Key Headlines Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $58 price target, substantially above recent trading levels. The analyst still projects Liquidia will remain profitable, with estimated EPS of $2.72 in fiscal 2026 rising to $6.14 by 2030. HC Wainwright Estimates Liquidia’s Q3 Earnings
• Neutral Sentiment: HC Wainwright lowered its estimates for third-quarter 2026 EPS to $0.76 from $1.01 and fourth-quarter EPS to $0.70 from $1.18. The firm also reduced its full-year forecasts through 2030, but its long-term estimates still imply earnings growth and remain above the current-year consensus estimate of $2.34 per share. Liquidia earnings estimate revisions
• Negative Sentiment: A federal court found that two United Therapeutics patent claims were valid and infringed by YUTREPIA’s use in pulmonary hypertension associated with interstitial lung disease. Liquidia plans to remove that indication from the product label, raising concerns about potential limits on availability and the company’s previously projected revenue growth. Liquidia Falls as Patent Ruling Overhang Continues
• Negative Sentiment: Levi & Korsinsky announced an investigation into whether Liquidia properly disclosed risks related to the patent ruling and its forecast of more than $1 billion in 2027 net revenue. The legal uncertainty is particularly material because YUTREPIA generated approximately $170.4 million in second-quarter net product sales. Liquidia Investigation Notice
• Negative Sentiment: Reported insider activity has been heavily weighted toward sales, including transactions by senior executives, adding another source of investor caution.

Hedge Funds Weigh In On Liquidia

Institutional investors and hedge funds have recently modified their holdings of the stock. Globeflex Capital L P purchased a new stake in Liquidia during the 2nd quarter valued at $175,000. Nykredit A S purchased a new position in Liquidia during the second quarter worth $177,000. Fluent Financial LLC purchased a new position in Liquidia during the second quarter worth $287,000. WINTON GROUP Ltd bought a new position in Liquidia during the second quarter valued at $335,000. Finally, Fulcrum Equity Management bought a new position in Liquidia during the second quarter valued at $399,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia Trading Down 6.3%

The firm has a market cap of $2.32 billion, a PE ratio of 18.91 and a beta of 0.61. The company has a quick ratio of 2.12, a current ratio of 2.31 and a debt-to-equity ratio of 0.63. The company’s 50 day moving average price is $69.27 and its two-hundred day moving average price is $62.07.

Liquidia (NASDAQ:LQDA) last released its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%.The firm had revenue of $171.68 million during the quarter, compared to the consensus estimate of $168.48 million. During the same quarter last year, the business posted ($0.49) EPS. Liquidia’s revenue was up 1842.1% compared to the same quarter last year. As a group, sell-side analysts forecast that Liquidia Corporation will post 2.1 EPS for the current year.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).